Medical, Office and Portfolios - Esthetician Leadership Today

U.S. FDA Clears Avita Medical’s Cohealyx for Healing Full-thickness Wounds

The Dermatology Digest

DECEMBER 20, 2024

Branded by AVITA Medical and co-developed with Regenity Biosciences, Cohealyx may reduce treatment timelines, and improve patient outcomes in the treatment of full-thickness wounds. AVITA Medical plans to develop clinical data for Cohealyx in early 2025 to build on the preclinical success and support the products commercial launch.

Portfolios

Portfolios Collagen Hospital Clinic

PHysicians & the esthetician

Southeastern Esthetics Institute

AUGUST 23, 2016

Estheticians and consumers alike understand the advanced changes that can be made within a medical setting - and physicians are realizing the supportive role that Estheticians can bring to their practices. Working in a medical setting as an Esthetician can be both rewarding and beneficial for both yourself and your clients alike.

Esthetician

Esthetician Esthetics Document Office

Dr Godfrey Town Ph.D re-Certifies as Laser Protection Adviser

Online Laser Training

APRIL 4, 2024

Our Online Laser Training International Programme Director, Dr Godfrey Town has been re-certified from 1st May 2023 by RPA 2000 for a further five years to act as a Laser Protection Adviser (LPA) and Dr Town holds this for medical, research and teaching.

Portfolios

Portfolios Training Office Medical

Alexis (Lexi) Stern Named New CMO at Merz Aesthetics

The Dermatology Digest

MARCH 27, 2024

Alexis (Lexi) Stern is Merz Aesthetics’ new Chief Marketing Officer. Stern will join the global leadership team and will be responsible for leading the portfolio and brand strategies. Stern will report directly to Bob Rhatigan, Chief Executive Officer, Merz Aesthetics. Most recently, Ms.

Office

Office Portfolios Branding Marketing

Why Nurses Are Moving to Aesthetic Medicine

AAAMS

FEBRUARY 22, 2023

Unfortunately, a steep road awaits nurses who exit the medical field entirely. If you’re still passionate and ambitious when it comes to working in the medical field, consider pivoting to a different sector of health care: aesthetic medicine! Practitioners are free and encouraged to exercise their best medical judgment.

Work-Life Balance

Work-Life Balance Training Office Marketing

Incyte, CMS Partner to Develop Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia

The Dermatology Digest

APRIL 1, 2024

We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” says Hervé Hoppenot, Chief Executive Officer, Incyte, in a news release.

Portfolios

Portfolios Injections Innovations Sales

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology

The Dermatology Digest

JANUARY 2, 2024

Brett Fair Named National Sales Director at Sun Pharma Brett Fair is now Sun Pharma’s National Sales Director for the medical dermatology sales team. In this role, Mr. Fair is responsible for the promotion of Winlevi and Absorica LD. Before joining Sun Pharma, he served as Vice President of Corporate Development at Novan Therapeutics.

Dermatology

Dermatology Sales Skincare Portfolios

Cosmetic Corner: Botox Biosimilar Update, New Launches From Cynosure Lutronic and HydraFacial

The Dermatology Digest

OCTOBER 1, 2024

“We are encouraged by the outcome from the recent FDA meeting and the opportunity to advance our development of prabotulinumtoxinA utilizing the 351(k) biosimilar regulatory pathway,” says Marc Forth, AEON’s President and Chief Executive Officer, in a news release. “We

Hydration

Hydration Portfolios Office Surgery

Evolus on the Move: Company Joins Forces With Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

The Dermatology Digest

DECEMBER 21, 2023

and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K. to now include the U.K.

Marketing

Marketing Sales Branding Portfolios

Evolus on the Move: Company Joins Forces With Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

The Dermatology Digest

DECEMBER 21, 2023

and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K. to now include the U.K.

Marketing

Marketing Sales Branding Portfolios

10 Best Nasal Sprays for COVID-19 (2023)

Aesthetics Advisor

SEPTEMBER 15, 2023

However, medications that are already authorized are just a small percentage of what's been studied. Many researchers are still trying to find and develop other medications that can treat or prevent COVID-19. It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement.

Hospital

Hospital Clinic Marketing Medical

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

The Dermatology Digest

NOVEMBER 4, 2024

The EU Medical Device Regulation (MDR) certification gave its nod to four injectable hyaluronic acid (HA) gel fillers from Evolus under the brand name Estyme, The CE Mark certification, through the new MDR process, represents more stringent requirements, designed to ensure the safety, efficacy, and quality of medical devices sold in Europe.

Injections

Injections Medical Portfolios Branding

U.S. FDA Approves Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

The Dermatology Digest

FEBRUARY 13, 2025

This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.

Injections

Injections Portfolios Safety Innovations

ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan

The Dermatology Digest

MARCH 27, 2025

We are thrilled to announce this agreement with Kaken, a dermatology leader with significant reach and expertise in the Japanese market, says Martin Babler, President and Chief Executive Officer of Alumis, in a news release. ESK-001 will be an important addition to the Kaken portfolio of novel therapeutics for dermatology conditions.

Pharmaceutical

Pharmaceutical Portfolios Clinic Safety

Esthetician Leadership Today

U.S. FDA Clears Avita Medical’s Cohealyx for Healing Full-thickness Wounds

PHysicians & the esthetician

Trending Sources

Dr Godfrey Town Ph.D re-Certifies as Laser Protection Adviser

Alexis (Lexi) Stern Named New CMO at Merz Aesthetics

Why Nurses Are Moving to Aesthetic Medicine

Incyte, CMS Partner to Develop Povorcitinib in Mainland China, Hong Kong, Macau, Taiwan, and Southeast Asia

TDD Industry News and Views: Weekly Updates on Comings, Goings, and Other Happenings in Dermatology

Cosmetic Corner: Botox Biosimilar Update, New Launches From Cynosure Lutronic and HydraFacial

Evolus on the Move: Company Joins Forces With Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

Evolus on the Move: Company Joins Forces With Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

10 Best Nasal Sprays for COVID-19 (2023)

Evolus Scores EU Approval of Estyme Injectable Hyaluronic Acid Gel Fillers Under New Medical Device Regulation Process

U.S. FDA Approves Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels

ESK-001 Update: Alumis, Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for the TYK2 Inhibitor in Japan

Stay Connected